The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
BSH 2022 | Treatment approaches for patients with R/R DLBCL: UK perspective
Wendy Osborne, MBBS (Hons), MRCP, FRCPath, Freeman Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle, UK, discusses treatment pathways and decision-making in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL) in the UK. Dr Osborne first highlights the importance of looking at whether a patient is fit enough for gemcitabine, dexamethasone, cisplatin (GDP) for first-line treatment. Following this, Dr Osborne explains the use of chimeric antigen receptor T-cell (CAR-T) therapy in patients who are not fit for chemotherapy. To conclude, Dr Osborne then discusses treatment options for patients who are not fit for CAR-T or high-dose chemotherapy, and how second-line decisions can affect third-line treatment options. This interview took place at the 62nd Annual Scientific Meeting of the British Society for Haematology (BSH) 2022, in Manchester, UK.
